TD Cowen Issues Positive Forecast for American Well (NYSE:AMWL) Stock Price

American Well (NYSE:AMWL) had its price target lifted by equities researchers at TD Cowen from $5.00 to $8.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm presently has a “hold” rating on the stock. TD Cowen’s price objective suggests a potential upside of 7.89% from the company’s current price.

Several other analysts have also recently issued reports on the company. Morgan Stanley upped their target price on American Well from $6.00 to $6.50 and gave the company an “equal weight” rating in a report on Wednesday. Weiss Ratings reissued a “sell (e+)” rating on shares of American Well in a report on Wednesday, January 21st. Stifel Nicolaus cut their price objective on shares of American Well from $6.00 to $5.00 and set a “hold” rating for the company in a research report on Friday, February 13th. Finally, Wall Street Zen upgraded shares of American Well from a “sell” rating to a “hold” rating in a report on Sunday, March 22nd. One investment analyst has rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $7.58.

American Well Price Performance

NYSE AMWL traded up $1.06 during trading hours on Wednesday, hitting $7.42. 161,781 shares of the company’s stock traded hands, compared to its average volume of 84,022. The firm’s 50-day moving average is $5.69 and its 200-day moving average is $5.03. American Well has a 52-week low of $3.71 and a 52-week high of $9.15. The company has a market capitalization of $122.72 million, a PE ratio of -1.25 and a beta of 1.52.

American Well (NYSE:AMWL) last issued its earnings results on Tuesday, May 5th. The company reported ($0.66) earnings per share for the quarter, topping the consensus estimate of ($0.77) by $0.11. The business had revenue of $54.88 million for the quarter, compared to analysts’ expectations of $51.54 million. American Well had a negative return on equity of 35.33% and a negative net margin of 38.38%. Equities research analysts predict that American Well will post -2.88 earnings per share for the current fiscal year.

Insider Buying and Selling at American Well

In related news, insider Dmitry Zamansky sold 5,575 shares of the business’s stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $5.30, for a total transaction of $29,547.50. Following the completion of the sale, the insider owned 241,080 shares in the company, valued at $1,277,724. The trade was a 2.26% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Over the last quarter, insiders sold 9,664 shares of company stock worth $51,219. 12.80% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On American Well

Several hedge funds and other institutional investors have recently bought and sold shares of AMWL. Rock Point Advisors LLC boosted its position in shares of American Well by 49.3% in the 3rd quarter. Rock Point Advisors LLC now owns 259,171 shares of the company’s stock valued at $1,594,000 after purchasing an additional 85,581 shares during the period. Monaco Asset Management SAM purchased a new position in shares of American Well during the fourth quarter worth about $338,000. Squarepoint Ops LLC raised its stake in American Well by 74.5% during the 4th quarter. Squarepoint Ops LLC now owns 115,061 shares of the company’s stock valued at $565,000 after acquiring an additional 49,135 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in American Well by 280.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 64,760 shares of the company’s stock worth $510,000 after acquiring an additional 47,745 shares during the period. Finally, Jane Street Group LLC increased its holdings in shares of American Well by 232.9% in the first quarter. Jane Street Group LLC now owns 64,112 shares of the company’s stock valued at $505,000 after purchasing an additional 44,852 shares during the period. 56.05% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting American Well

Here are the key news stories impacting American Well this week:

• Positive Sentiment: Q1 results: AMWL reported revenue of $54.9M (above the $51.5M consensus) and an EPS figure that topped some estimates (company reported ($0.66) vs. consensus around ($0.77)), signaling better-than-expected top-line performance and an EPS surprise. Amwell Q1 Press Release
• Neutral Sentiment: Revenue guidance: AMWL updated Q2 revenue guidance to $48M–$52M (consensus ~ $50.1M) and FY 2026 revenue guidance to $195M–$205M (consensus ~ $199.5M). Midpoints are essentially in line with Street expectations — reduces surprise risk but doesn’t materially change the growth outlook. GlobeNewswire: Q1 Results & Guidance
• Neutral Sentiment: Earnings call/transcript: Management commentary from the Q1 2026 earnings call may provide color on bookings, margin trajectory and product adoption — useful for gauging whether upside in revenue is sustainable. Seeking Alpha: Q1 2026 Call Transcript
• Negative Sentiment: Analyst positioning: Morgan Stanley raised its price target modestly from $6.00 to $6.50 but kept an “equal weight” rating — the new PT still implies downside versus the current share price, which may cap upside from analyst sentiment. TickerReport: Morgan Stanley PT Update

About American Well

American Well, operating under the trade name Amwell, is a Boston-based digital health company that develops and delivers telehealth solutions to healthcare providers, payers, employers and patients. Through its cloud-based platform, the company enables secure virtual visits, remote patient monitoring and integrated care coordination across a range of medical disciplines, including primary care, behavioral health, chronic disease management and urgent care.

The company’s core offering, the Amwell Telehealth Platform, facilitates live video consultations, asynchronous messaging, e-prescribing and electronic health record integration.